Health and Fitness Health and Fitness
Wed, September 29, 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Alnylam Publishes Results from Phase IIa Study of .. f Respiratory Syncytial Virus Infection in Lung T
[ Wed, Sep 29th 2010 ] - Market Wire
YM BioSciences licensee Pulmokine awarded NIH fun .. p small molecule drugs for pulmonary hypertension
[ Wed, Sep 29th 2010 ] - Market Wire
CENTRIC HEALTH ESTABLISHES PHARMACY DIVISION
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc pubblicher i risultati del quarto trimestre il 9 novembre 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc gibt Ergebnisse des vierten Quartals am 9. November 2010 bekannt
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc pr©sentera ses r©sultats du quatrime trimestre le 9 novembre 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Quidel Announces FDA Clearance of Its QuickVue® RSV 10 Immunoassay Diagnostic Test
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc Divulgar Resultados do Quarto Trimestre em 9 de Novembro de 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc presentar los resultados correspondi .. tes al cuarto trimestre el 9 de noviembre de 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc to Report Fourth-Quarter Results on November 9, 2010
[ Wed, Sep 29th 2010 ] - Market Wire
BD Diagnostics and Bruker Collaborate to Improve .. fication and Antimicrobial Susceptibility Testing
[ Wed, Sep 29th 2010 ] - Market Wire
Wellstar International, Inc. Announces the Result .. n of the Duke University Study Have Been Accepted
Tue, September 28, 2010
[ Tue, Sep 28th 2010 ] - Market Wire
Prospect Medical Holdings, Inc. Announces End of aGo-Shopa Period
[ Tue, Sep 28th 2010 ] - Market Wire
Medtronic Advances Research on Drug-Eluting Balloons for Coronary and Peripheral Artery Disease
[ Tue, Sep 28th 2010 ] - Market Wire
HealthSpring, Inc. Announces the Addition of John T. Fox to Its Board of Directors
[ Tue, Sep 28th 2010 ] - Market Wire
Medtronica?s Insertable Cardiac Monitor Documented Arrhythmias in Post-Heart Attack Patients
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien far Apresentao na conferncia "Jefferies European Healthcare Conference"
[ Tue, Sep 28th 2010 ] - Market Wire
Aetna Becomes First Georgia Insurer to Cover Medically Fragile Children for aDream Housea?
[ Tue, Sep 28th 2010 ] - Market Wire
Nicusa Capital Calls for Leadership Changes at BioClinica
[ Tue, Sep 28th 2010 ] - Market Wire
Synergetics USA to Present at Craig-Hallum Capital Group 2010 Alpha Select Conference
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien presenteert tijdens congres Jefferies European Healthcare
[ Tue, Sep 28th 2010 ] - Market Wire
CellCyte Genetics Corp. Announces the Appointment of Douglas Pat Cerretti, Ph.D. to President
[ Tue, Sep 28th 2010 ] - Market Wire
Biojector®2000 Utilized in a Human Clinical Trial of DNA-MVA HIV Vaccine
[ Tue, Sep 28th 2010 ] - Market Wire
XenoPort Announces Presentation of New Data for XP21279 at World Parkinson Congress
[ Tue, Sep 28th 2010 ] - Market Wire
Amedisys Receives Civil Investigative Demand from the U.S. Department of Justice
[ Tue, Sep 28th 2010 ] - Market Wire
Health Net, Inc. to Hold Conference Call and Webc .. st to Discuss Third Quarter 2010 Earnings Results
[ Tue, Sep 28th 2010 ] - Market Wire
St. Jude Medical Announces Principal Investigator .. r Aortic Valve Implantation (TAVI) Clinical Trial
[ Tue, Sep 28th 2010 ] - Market Wire
Rochea?s New RTCA Cardio Instrument for Label-Free Functional Cardiomyocyte Toxicity Testing
[ Tue, Sep 28th 2010 ] - Market Wire
International Stem Cell Corporation Announces Sig .. ation of the First Bank of Immune-Matched Human P
[ Tue, Sep 28th 2010 ] - Market Wire
ARIAD to Present at the Jefferies Global SpecPharma and European Healthcare Conference

ARIAD to Present at the Jefferies Global SpecPharma and European Healthcare Conference


Published on 2010-09-28 04:45:14 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it is scheduled to present at the Jefferies Global SpecPharma and European Healthcare Conference being held in London, England. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, October 5, 2010 at 12:30 p.m. local time.

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://investor.ariad.com ]. A replay of the presentation will be available on the ARIAD website approximately 24 hours after the presentation and will be archived for three weeks.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in pivotal Phase 2 clinical development in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].

Contributing Sources